BBI-3000 is under clinical development by Fresh Tracks Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BBI-3000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBI-3000 is under development for the treatment of cutaneous T cell lymphoma and breast cancer. It is administered topically and orally. It is a rexinoid and acts by targeting the retinoid X receptor. It was also under development for acne and psoriasis.
Fresh Tracks Therapeutics overview
Fresh Tracks Therapeutics formerly Brickell Biotech, discovers and develops pharmaceutical products for inflammatory, autoimmune and other debilitating diseases. The company is investigating BBI-02, an oral DYRK1A inhibitor to treat atopic dermatitis, rheumatoid arthritis and type 1 diabetes: BBI-03, a topical DYRK1A inhibitor targeting dermatological autoimmune diseases. It is also evaluating BBI-10, an orally available covalent STING inhibitor for inflammatory diseases and rare monogenic disorders. Brickell Bio develops is products based on its proprietary novel kinase inhibitor platform, a library of new chemical entities. The company partners with pharmaceutical, biotechnology companies, government agencies and research institutions. Fresh Tracks Therapeutics is headquartered in Boulder, Colorado, the US.
For a complete picture of BBI-3000’s drug-specific PTSR and LoA scores, buy the report here.